seekingalpha.com Market update
AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo
[A big sign with AstraZeneca logotype outside the entrance.] Wirestock * AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded the drug was unlikely to meet either primary endpoint, according to a statement on Monday. * The IDMC concluded that the volrustomig …